Clinical Trials Logo

Lung Fibrosis clinical trials

View clinical trials related to Lung Fibrosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05648734 Completed - Clinical trials for Post-COVID-19 Syndrome

Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis

Start date: March 10, 2022
Phase:
Study type: Observational

In this study we aim to evaluate the radiological and functional changes in post-acute covid-19 pulmonary fibrosis patients in relation to anti-inflammatory and/or antifibrotic drugs prescribed during and after covid-19 pneumonia.

NCT ID: NCT04274257 Completed - Autoimmune Diseases Clinical Trials

A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis

DesiReS
Start date: December 4, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluates the efficacy and safety of rituximab compared with placebo in SSc patients. This study consists of a 24-week, double-blind, placebo-controlled period followed by a 24-week active drug treatment period.

NCT ID: NCT01570764 Completed - Systemic Sclerosis Clinical Trials

Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease

SCLEROCYC
Start date: January 14, 2013
Phase: Phase 3
Study type: Interventional

By including in this study patients with significant worsening of their lung volumes and / or their DLCO (carbon monoxide diffusing capacity) in the previous year, on the basis of an open retrospective study we recently conducted, we hope to demonstrate that a strategy combining prednisone and intravenous cyclophosphamide therapy is accompanied by an increase in the frequency stabilization / improvement of lung volumes and / or DLCO of patients at 12 months of 15% in the placebo and prednisone cyclophosphamide 50% in cyclophosphamide and prednisone.We also hope to demonstrate significant decrease in the number of patients excluded for failure in the CYC arm as compared to the placebo arm.